Effects of IL17/23 Inhibitors on Markers of Subclinical Atherosclerosis in Patients with Psoriasis: An Observational Study
Both IL-23 and IL-17 inhibition exhibited comparable improvement of arterial stiffness in patients with psoriasis. Further studies are needed to evaluate the long-term impact of biologics on the cardiovascular status of these patients. Retrospectively registered ClinicalTrials.gov identifier: NCT07169682. A Graphical abstract is available for this article.
Authors
- Alexander Stratigos (ORCID: https://orcid.org/0000-0002-6088-5694)
- Στέργιος Σουλαϊδόπουλος (ORCID: https://orcid.org/0000-0003-4150-5286)
- Stamatios Gregoriou (ORCID: https://orcid.org/0000-0002-7585-1032)
- Charalambos Vlachopoulos (ORCID: https://orcid.org/0000-0002-9904-3558)
- Marina Papoutsaki (ORCID: https://orcid.org/0000-0002-2422-0994)
- Panagiotis Kostakis
- Natalia Rompoti (ORCID: https://orcid.org/0000-0002-9326-6726)
- Konstantinos P Tsioufis (ORCID: https://orcid.org/0000-0002-7636-6725)
- Aikaterini Tsiogka (ORCID: https://orcid.org/0000-0002-6853-9788)
- George Kontochristopoulos
- Dimitrios Rigopoulos
- Pantelis Panagakis
Institutions
- Hygeia Hospital (GR)
- Andreas Sygros Hospital (GR)
- Hippocration General Hospital (GR)
Publication Details
- Journal
- Dermatology and Therapy
- Published
- 2025-10-08
- DOI
- https://doi.org/10.1007/s13555-025-01549-1
- Primary Topic
- Psoriasis: Treatment and Pathogenesis
- Type
- article
- Field-Weighted Citation Impact
- 0.00